Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
← catalyst calendarNCT06677060 · readout in 1,216 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
11,300estimated
Sites
953
Countries
Argentina, Australia, Brazil +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-14 | actual | When the study began enrolling |
| Primary completion | 2029-12-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Interventions
- Drug: Baxdrostat and dapagliflozin — also filed as Baxdrostat CIN-107
- Other: Placebo and dapagliflozin
Primary outcome
what the primary-completion date above is the date OFTo determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV death
measured Event driven; Up to 38 months
Publications
- PMID 40913594 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed